HRSA ADR Panel Dismisses NACHC's 340B Complaint Against Two Drug Manufacturers | Foley Hoag LLP

The 340B program requires drug manufacturers to offer outpatient pharmaceuticals to statutorily defined covered entities (including certain hospitals and certain federal grantees, such...

Related Keywords

Delaware ,United States ,Indiana ,Astrazeneca Pharm ,Eli Lilly ,Foley Hoag ,Human Services ,Health Resources ,District Court ,National Association Of Community Health Centers ,Astrazeneca ,Department Of Health ,Services Administration ,B Drug Pricing Program ,Office Of Management ,Administrative Dispute Resolution ,National Association ,Community Health Centers ,Patient Protection ,Affordable Care Act ,Final Rule ,Drug Pricing Program ,Administrative Procedure Act ,Southern District ,Advisory Opinion ,